CANCER KILLER?
Researchers seek clinical trials for extract
Researchers study whether dandelion root extract kills cancer cells.
WINDSOR, Ont. — Cancer researchers in Windsor hope to start clinical trials soon to find out if dandelion root extract can kill cancer cells in humans without harming healthy cells.
“We are very excited,” said Dr. Siyaram Pandey, a biochemist at the University of Windsor, describing the result of the tests in the lab that so far confirm that dandelion root extract causes cancer cells from leukemia blood samples to die off.
He and oncologist Dr. Caroline Hamm of Windsor Regional Hospital are submitting their application to Health Canada for approval of a Stage 1 clinical trial to determine just what dose of dandelion root extract is tolerable and effective in patients with an aggressive form of leukemia known as chronic myelomonocyctic leukemia, as well as other cancers, including pancreatic cancer and melanoma.
The research could one day lead to a cancer treatment that is nontoxic and not derived from synthetic chemicals.
“It triggers a very specific kind of suicide,” Pandey said of the process in which the dandelion root extract causes cancer cells to die.
“The fantastic observation was that it was very selective to cancers.”
In other words, the extract only targeted cancer cells and not healthy cells.
This is a contrast to current chemotherapy treatments, which are very toxic and damage normal cells in the process of killing cancerous ones.
Pandey said that the same cell suicide result was observed when the dandelion root extract was applied to other types of cancers, including bone cancer, pancreatic cancer, colon cancer and neuroblastoma.
Research conducted in mice has shown no toxicity either, Pandey said, and it showed the dandelion root extract had no side effects.
The team’s latest findings were published Friday in the journal PLOS One.
Another paper is set to be published next month in the journal of the American Pancreatic Association.
Pandey said he hopes to meet with Health Canada in the next few months to discuss the potential for the clinical trial on humans.
“We’re early on,” Hamm said, adding that if Health Canada does approve the clinical trial, she expects it will go quickly because there will be a lot of interest.